XTX Topco Ltd Invests $216,000 in Septerna, Inc. (NASDAQ:SEPN)

XTX Topco Ltd purchased a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 37,350 shares of the company's stock, valued at approximately $216,000. XTX Topco Ltd owned 0.08% of Septerna at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. purchased a new position in shares of Septerna in the 4th quarter valued at about $22,557,000. JPMorgan Chase & Co. purchased a new position in shares of Septerna in the 4th quarter valued at about $871,000. Geode Capital Management LLC purchased a new position in shares of Septerna in the 4th quarter valued at about $8,717,000. Wells Fargo & Company MN purchased a new position in shares of Septerna in the 4th quarter valued at about $244,000. Finally, Invesco Ltd. purchased a new position in shares of Septerna in the 4th quarter valued at about $278,000.

Septerna Trading Down 2.5%

NASDAQ SEPN opened at $11.20 on Wednesday. The business's 50-day moving average price is $11.44 and its 200 day moving average price is $9.25. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The company has a market capitalization of $499.07 million and a PE ratio of -1.11.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). Septerna had a negative return on equity of 35.82% and a negative net margin of 12,053.03%. The firm had revenue of $0.12 million during the quarter, compared to analysts' expectations of $22.50 million. Equities analysts predict that Septerna, Inc. will post -7.11 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SEPN shares. HC Wainwright started coverage on Septerna in a research note on Monday, June 23rd. They issued a "buy" rating and a $26.00 price objective for the company. Wells Fargo & Company raised their target price on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th. Finally, Cantor Fitzgerald raised their target price on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Septerna has an average rating of "Moderate Buy" and a consensus target price of $26.75.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.